Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 27  •  02:58PM ET
15.25
Dollar change
-1.15
Percentage change
-7.01
%
Today, 11:35 AMZ Squared to begin Nasdaq Global Market trading as ZSQR as Coeptis share distribution takes effect today
Index
-
P/E
-
EPS (ttm)
-2.80
Insider Own
18.15%
Shs Outstand
5.75M
Perf Week
-
Market Cap
-
Forward P/E
-
EPS next Y
-
Insider Trans
-
Shs Float
5.19M
Perf Month
-
Enterprise Value
-
PEG
-
EPS next Q
-
Inst Own
7.47%
Perf Quarter
-
Income
-10.91M
P/S
-
EPS this Y
-
Inst Trans
-
Perf Half Y
-
Sales
1.36M
P/B
5.08
EPS next Y
-
ROA
-70.73%
Perf YTD
-
Book/sh
3.00
P/C
-
EPS next 5Y
-
ROE
-96.83%
52W High
- -
Perf Year
-
Cash/sh
-
P/FCF
-
EPS past 3/5Y
62.31% 40.22%
ROIC
-62.70%
52W Low
- -
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-207.81%
Volatility
- -
Perf 5Y
-
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
50.41%
Oper. Margin
-956.94%
ATR (14)
9.80
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
4.16
Sales Y/Y TTM
-
Profit Margin
-800.38%
RSI (14)
-
Dividend Gr. 3/5Y
- -
Current Ratio
4.16
EPS Q/Q
80.71%
SMA20
0.00%
Beta
-
Payout
-
Debt/Eq
0.02
Sales Q/Q
-
SMA50
0.00%
Rel Volume
-
Prev Close
16.40
Employees
6
LT Debt/Eq
0.01
Earnings
-
SMA200
0.00%
Avg Volume
-
Price
15.25
IPO
-
Option/Short
No / No
EPS/Sales Surpr.
- -
Trades
Volume
162,066
Change
-7.01%
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.